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An Abstract of the Scholarly Project by 
Morgan B. Baxter 
 
 
 This scholarly project included an education presentation to Pittsburg State 
University students enrolled in the Health Promotion class in the Fall of 2019, a pretest 
was taken before the educational presentation and then a posttest was completed to assess 
the student’s knowledge of HPV and the HPV vaccine. The posttest evaluated whether 
there was an increase in knowledge after the presentation. In this scholarly project there 
was an overall increase in knowledge with statistical significance (p<0.05) after the 
presentation of evidence-based practice information of HPV and the HPV vaccine. There 
was an increase in posttest scores after the presentation in all participants (n=58). Current 
research states overall low HPV vaccine uptake and this study shows that many college 
students are not aware of HPV and HPV vaccine evidence-based information. This 
project validates the need for continued education for students of HPV and the HPV 





















TABLE OF CONTENTS 
CHAPTER...................................................................................................................PAGE 
I. INTRODUCTION............................................................................................................1  
Background..............................................................................................................2 
Significance of the Problem.....................................................................................4 
Significance to Nursing............................................................................................5  
Specific Aims/ Purpose............................................................................................6  
Theoretical Framework............................................................................................6 
Project Questions.....................................................................................................7  




II. LITERATURE REVIEW..............................................................................................13 
Purpose...................................................................................................................13 
Literature Review...................................................................................................14  
 Method.......................................................................................................14  
 Practice Change Guidelines.......................................................................14 
   Selection of Best Practice Guidelines............................................14 
 Lack of Information...................................................................................19  
 Lack of Education......................................................................................20  
 Beliefs........................................................................................................22 




III. METHODOLOGY......................................................................................................26  
Project Design........................................................................................................26 
Settings and Participants........................................................................................28 
  Recruitment................................................................................................28  
Inclusion/Exclusion Criteria......................................................................29  
Protection of Human Subjects...............................................................................29 
Ethical Considerations...........................................................................................30 
Instrument..............................................................................................................30 
  Content Validity.........................................................................................31 
Operational Definitions..........................................................................................31 
Procedure...............................................................................................................32  
Data Collection......................................................................................................33  
Outcome Data........................................................................................................33 
Outcomes...............................................................................................................34  
Evaluation Measures Linked to Objectives...............................................34 
Instrument Linked to Measures and Objectives.........................................34 











IV. FINDINGS...................................................................................................................39  
Introduction............................................................................................................39  
Demographic Data.................................................................................................39  
Pretest and Posttest................................................................................................41 
Results of the Study...............................................................................................42  
Individual Comparison of Pretest and Posttest......................................................43  
Summary................................................................................................................45 
 
V. SUMMARY, CONCLUSIONS, RECOMMENDATIONS.........................................47  
Introduction............................................................................................................47  
Relationships of Outcomes to Research................................................................47  
Observations..........................................................................................................48  
Evaluation of Theoretical Framework...................................................................48  
Evaluation of Logic Model....................................................................................49  
Limitations.............................................................................................................50  
Implications for Future Projects.............................................................................50  
















LIST OF TABLES 
TABLE........................................................................................................................PAGE 
1. Application of the Health Belief Model ..........................................................................7 
2. Summary of General Best Practice Guidelines for Immunizations...............................15  
3. Objectives, Measurements, and Outcomes....................................................................35  
4.  Gender of Participants...................................................................................................40  
5. Has the Respondent Ever Heard of the HPV Vaccine...................................................40  
6. Has the Respondent Ever heard of HPV........................................................................41 
7. Has a Healthcare Provider Recommended the HPV Vaccine to the Respondent..........41 
8. Has the Respondent Received at Least One Dose of the HPV Vaccine........................41 
9. HPV Knowledge on Pretest and Posttest ......................................................................42 














LIST OF FIGURES 
FIGURE.......................................................................................................................PAGE 
1. Logic Model...................................................................................................................11  
2. Study Design..................................................................................................................27 























The most common sexually transmitted infection (STI) is the human 
papillomavirus (HPV). HPV is a family of viruses that infects the epithelial tissue of 
males and females. Many people are exposed to this virus without symptoms. Before 
there was a vaccine for HPV, approximately 17 million young adults aged 15-24 years 
old had a prevalent HPV infection. It is likely almost every person will be infected with 
HPV in their lifetime (Centers for Disease Control and Prevention, 2019). Due to the 
many different strands of HPV sometimes the body is able to get rid of the disease 
without symptoms or disease and other times the strand can cause the person cancer. The 
STI is known to cause at least six types of cancer and genital warts (Satterwhite et al., 
2013). More than 90% of cervical cancer and 63-75% of vulvar, vaginal, oropharyngeal, 
and penile cancer can be linked to HPV (Steinau et al., 2013). A vaccine was approved in 
2014 that prevents HPV and HPV outcome related diseases (Centers for Disease Control 
and Prevention [CDC], n.d.). The HPV vaccine uptake has increased since 2013, from 
19.6% to 29.5% of Kansans being vaccinated. This is significantly below the Healthy 
People 2020 goal of 80% vaccine uptake (Gillespie, 2018).  The HPV vaccine is essential 
to the public to protect from diseases that have serious side effects and can possibly result 










There are more than 150 subtypes of HPV that have been identified. Some HPV 
subtypes can cause common warts, such as those on the hands and feet by infecting 
cutaneous epithelial cells. At least 40 of the subtypes of HPV can involve the areas of 
genitals, mouth, and throat by infecting the mucosal epithelial cells. (CDC, n.d.). Once 
infected with HPV many people do not know they have the virus because they 
are asymptomatic and resolve without complication. In some cases, HPV lasts 
longer than two years and can cause certain cancers of the cervix, vulva, and 
vagina, in women; cancer of the penis in men; and cancers of the back of the 
throat, anus, tongue, and tonsils in both genders (CDC, 2018c). HPV type 16 and 
18 are high-risk viruses and cause 80% of the cancers from HPV. Genital warts 
and possibly laryngeal papillomas are caused by the lower risk HPV types. Both 
subtypes can cause low-grade cervical cell changes. Low-risk HPV types 6 and 
11 almost always cause genital warts and papillomas (CDC, n.d.) 
HPV is spread by anal, vaginal, and oral sex, with someone who has the 
HPV virus. The virus is most commonly spread by vaginal and anal sex. In the 
United States, there have been three different HPV vaccines available: two are 
U.S. Food and Drug Administration (FDA) approved include Gardasil  
(Quadrivalent) and Gardasil 9 (9-valent). Gardasil 9 was approved in 2014, it 
was studied with more than 15,000 participants before the vaccine was released 
and is continually monitored by the CDC. Gardasil 9 has been the only HPV 
vaccine available since 2016 in the United States. This vaccine protects against 









cause cancer. The original Gardasil was approved in 2006, this vaccine was 
tested was on more than 29,000 individuals. Gardasil protects against HPV types 
6, 11, 16, and 18 (CDC, 2018d). Cervarix, the 3rd HPV vaccine has been 
discontinued due to lack of use because of Gardasil. HPV causes approximately 
32,500 cancers each year, 30,000 of those are preventable with the current HPV 
vaccine (CDC, n.d.) 
  The HPV vaccine is recommended for patients between the ages of 9 to 26 for 
women ages 9 though 21 for men. The vaccine is recommended for transgender patients 
and for men that have sex with men until age 26. Recommendations state children age 11 
or 12 should get the vaccine before they become sexually active and can receive the 
vaccine as early as nine years old. Two vaccines six to 12 months apart are required to be 
fully vaccinated against HPV. If the child is over 14 years of age the child still qualifies 
for the vaccine, but three injections are needed six months apart to be fully vaccinated 
against HPV. If a patient is immunocompromised, three doses is recommended regardless 
of age or gender (CDC, 2018c). Recommendations are to receive the full recommended 
doses of the HPV vaccine before becoming exposed to HPV. Even if you contract one 
strain of HPV the vaccine will protect you from the other strains of HPV the vaccine 
covers. The vaccine can still be given if the person receiving the vaccine is ill with a 
minor illness such as an upper respiratory tract infection, without or with a fever, or 
diarrhea. If a woman has had an abnormal pap, positive HPV test, or genital warts she is 
still able to receive the vaccine, but the vaccine may not be as effective based on the 
existing HPV infection. Women that are currently breastfeeding are able to safely obtain 









known allergy to the Gardasil vaccine or hypersensitivity to yeast, a severe or moderate 
illness, and pregnancy. Although studies have shown the HPV vaccine does not harm the 
mother or fetus. A negative pregnancy test is not needed before vaccine administration 
(Centers for Disease Control and Prevention, n.d.) The vaccination is not recommended 
for adults older than 26 years of age since the vaccination provides less benefit from 
possible prior exposure to HPV. Engaging with a new sexual partner is a risk for a new 
HPV infection. The vaccine will not treat any existing HPV infections but does prevent 
new HPV infections (CDC, 2019).  
  Research conducted in Kansas states that females are twice as likely to receive at 
least one dose of the vaccine compared to males. If the child is older, 15 to 17 years of 
age, they are twice as likely to receive at least one dose of the vaccine compared to 
younger children. Also, in Kansas it was shown that more populated urban counties are 
1.5 times likely to receive at least one dose of the vaccine compared to rural counties 
(Gillespie, 2018).  One reason children are not being vaccinated is low caregiver 
education level (Forshaw et al., 2017). There are many different reasons parents choose 
not to vaccinate or delay vaccination including: medical, religious, philosophical, or 
socioeconomic status (Ventola, 2016). 
Significance of the Problem 
HPV is a virus that is very common. Approximately 80 million or one in four 
people have the HPV virus in the United States. On average, 14 million people contract 
the HPV virus every year, mostly teens and young adults. Yearly HPV causes 33,700 
cancers in women and men from the HPV infection (Centers for Disease Control and 









20,000 approximately cancers that are non-cervical each year in the United States. 
Oropharyngeal cancer caused by the HPV infection affects approximately 10,100 men in 
the United States each year. Approximately 12,000 women are diagnosed with cervical 
cancer each year with recommended screening and treatment. It is said that more than 
4,000 women die every year in this country from cervical cancer (Centers for Disease 
Control and Prevention, n.d.).  
 The only cancer caused by HPV providers screen for routinely is cervical cancer. 
Other types of HPV are not usually detected and explored until the person becomes 
symptomatic. Because of this prevention is key. Starting at age 21 routine cervical cancer 
screening begins and continues through age 65. Even with the HPV vaccine, routine 
cervical cancer screenings should take place as recommended. The HPV vaccine is safe 
and effective. Several studies have shown the vaccine to be effective in protecting against 
HPV for greater than 10 years. Ongoing research is being conducted on HPV and the 
HPV vaccine (Centers for Disease Control and Prevention, n.d.). Despite this research 
vaccination rates remain lower than the Healthy People 2020 goal of 80% vaccination 
uptake in Kansas and United States as a whole (Gillespie, 2018).  
Significance to Nursing 
 This subject plays a part to nursing in many ways. Advanced practice 
registered nurses (APRN) manage many individuals preventative care. Educating 
the patient as well as their parent or guardian if applicable of HPV and the 
benefits of the HPV vaccine is essential. Health care providers are key in routine 











This study will assess the knowledge of a health promotion class in the fall of 
2019 at Pittsburg State University in Pittsburg, Kansas, before and after an educational 
presentation of HPV and the HPV vaccine, by survey administration. Resources of where 
the HPV vaccine can be obtained will be communicated to the students.  
The aims of this study includes informing college students about HPV and the 
HPV vaccine and assessing knowledge before and after education is obtained about HPV 
and the HPV vaccine. The students in this project are enrolled in the fall 2019 Health 
Promotion class offered at Pittsburg State University. This class is open to all majors 
including pre-nursing and exercise science. It is possible that many of these students will 
one day be in involved in healthcare. This will likely increase knowledge of HPV and 
HPV vaccine in the healthcare field and the general public.  
Theoretical Framework 
The Health Belief Model (HBM) can be applied to increasing HPV and HPV 
vaccine knowledge and uptake. This model was initially used on low response of free 
tuberculosis screening. Since the 1950’s, this framework is often used to understand 
health behavior and promote health practices (University of Twente, 2017).  
There are three major assumptions of this framework. The HBM implies that a 
person will engage in a health-related action if the person feels the undesirable health 
condition can be avoided; has an expectation that by utilizing a recommended practice, 
he/she avoid the undesirable health condition; and believes that he/she can successfully 
take the suggested health action.  There are six concepts to this model including: 









to action, and self-efficacy. All assumptions and concepts of this model can be applied to 
this topic (University of Twente, 2017). 
Table 1: 
Application of the Health Belief Model  
Concept Definition HPV vaccine  
1.     Perceived susceptibility “One's opinion of 
chances of getting a 
condition” 
Persons <26 years of age 
believe they can acquire 
HPV. 
2.     Perceived severity “One's opinion of how 
serious a condition and 
its consequences are” 
Persons <26 believe that the 
consequences of getting 
HPV are significant enough 
to try to avoid. 
3.     Perceived benefits “One's belief in the 
efficacy of the advised 
action to reduce risk or 
seriousness of impact” 
Persons <26 believe that the 
suggested action of the HPV 
vaccine would protect them 
from getting HPV. 
4.     Perceived barriers “One's opinion of the 
tangible and 
psychological costs of 
the advised action” 
Persons  <26 identify 
personal barriers to getting 
the HPV vaccine and 
explore ways to eliminate or 
reduce barriers. 
5.     Cues to action “Strategies to activate 
"readiness”” 
HPV vaccine information 
will be presented. An 
incentive will be presented 
to Persons <26 who receive 
the HPV vaccine. 
6.     Self-efficacy “Confidence in one's 
ability to take action” 
Persons <26 will be 
confident in the HPV 
vaccine protecting them 
against HPV. 
Reproduced from University of Twente, 2017 
Project Questions 
The practice problem identified is low HPV vaccine rates in the state of Kansas, 
this leads to increased risk and exposure of HPV that can lead to cancer and other chronic 
health conditions. The aim of this project is to evaluate the knowledge of HPV and the 









with evidence-based facts. This project will assess whether the education provided 
increased knowledge of HPV and the HPV vaccine. Research questions in this project 
include:  
1. What are the demographics (gender and age) of the respondents? 
2. Will students have heard of the HPV vaccine pre-education? 
3. Will students have heard of HPV pre-education? 
4. What is the respondent’s HPV knowledge pre-education? 
5. Has a healthcare provider recommended the HPV vaccine to the respondent? 
6. Has the respondent received at least one dose of the HPV vaccine series?  
7. What is the respondent’s HPV knowledge post-education? 
8. Did education increase the knowledge of HPV post-education? 
Definition of Key Terms/Variables 
Terms that may not be recognized by colleagues or review include: Centers for 
Disease Control and Prevention (CDC), college-aged, Gardasil, Gardasil 9, human 
papillomavirus (HPV), immunity, vaccination, vaccine, and vaccination uptake. 
1. Centers for Disease Control and Prevention (CDC) – A major group that 
oversees and tracks health related issues and diseases for the United States 
government. The CDC is an agency that is recognized as the nation’s 
premiere health promotion, preparedness, and prevention agency (Centers 
for Disease Control and Prevention, 2018a).  
2. College-aged – The general age in which students generally attend a 









3. Gardasil – The first approved HPV vaccine in 2006. Safety of this vaccine 
was proven by clinical trials of more than 29,000 participants and 
continues to be monitored. This vaccine only protects against 4 strains of 
HPV: 6, 11, 18, and 18 (CDC, 2018d). 
4. Gardasil 9 (9-valent) – Also referred to as the HPV vaccine. The only 
current HPV vaccine used in the United States that prevents nine types of 
HPV: 6, 11, 16, 18, 31, 33, 45, 52, and 58. This vaccine was studied with 
15,000 participants before approved by the FDA in 2014 and continues to 
be monitored (CDC, 2018d).  
5. Human papillomavirus (HPV) – “A type of virus that can cause abnormal 
tissue growth (for example, warts) and other changes to cells. Infection for 
a long time with certain types of human papillomavirus can cause cervical 
cancer. Human papillomavirus may also play a role in some other types of 
cancer, such as anal, vaginal, vulvar, penile, and oropharyngeal cancers. 
Also called HPV” (National Cancer Institute, n.d, para 1).   
6. Immunity – protection from a disease, if exposed you will not be infected 
(CDC, 2018e).  
7. Immunization – the process of obtaining protection though vaccination 
from diseases, also used interchangeably with vaccination, inoculation, or 
vaccination uptake (CDC, 2018e)  
8. Vaccination – receiving a vaccine that will allow the body to gain 









9. Vaccine – “A product that stimulates a person’s immune system to 
produce immunity to a specific disease, protecting the person from that 
disease. Vaccines are usually administered through needle injections but 
can also be administered by mouth or sprayed into the nose” (CDC, 2018e, 
para 2). 
10. Vaccination uptake – the process of obtaining a vaccination.  
Logic Model  
This logic model represents relationships starting with inputs, outputs, and 
outcomes. Short term outcomes include increasing HPV and HPV vaccine knowledge in 
college students, assessing pre and post education HPV and HPV vaccine knowledge. 
Medium term outcomes include an increase of HPV and HPV vaccine knowledge in 
students and the general public. A long-term outcome of this project is increasing HPV 
vaccine uptake. There are assumptions and external factors that contribute to the success 
of this project. Assumptions include students gaining knowledge from the education and 
the students taking the pre and posttest to the best of their ability. External factors include 















































































































Students will gain knowledge after the 
presentation and HPV vaccination rates 
will increase.   
Students will take the assessment to the 
best of their ability.  















HPV is a very common virus that most people contract throughout their lifetime. 
The number of people that remain unvaccinated in Kansas from HPV remains low, even 
though research shows the vaccine provides many benefits. This education focuses on 
providing education to Pittsburg State University undergraduate students from many 
majors including nursing and other health related majors. This knowledge will contribute 
to the knowledge of HPV in hopes to raise the HPV vaccination rate. Chapter II provides 





































Vaccines are one of the greatest defenses from deadly diseases. Vaccines have 
evolved over time and in recent years vaccines that protect against cancer have been 
developed. This literature review will focus on and describe the many different factors 
that lead to compliance of the two or three dose HPV vaccination that is obtained by the 
public from age 11 through 26. 
Purpose 
The purpose of this literature review is to analyze barriers that contribute to 
omitting the HPV vaccination and possible implications for the public and healthcare 
professionals including the advanced practice registered nurse. This literature review will 
examine what barriers; perceived or actual, prevent young adults and children from 
getting recommended vaccinations. Interventions that could be used to increase the rate 
of vaccinated young adults will be reviewed and how primary care providers can 
implement these interventions. Whether providers adequately communicate 
immunization education and benefits with patients, parents, and guardians will be 
analyzed. Factors that affect the status of a child being vaccinated include: lack of 











An electronic search was conducted using the database CINAHL Plus with full 
text to identify studies published between 2014-present. Articles researching the HPV 
vaccine have been published for over 13 years but for current information, the search was 
limited to the last five years. Search terms used were “HPV vaccine”. Only full-text, 
English articles in the geographic region of the United States was involved in the search. 
Initially searching for “HPV vaccine” with the above indications resulting in 146 results.  
Practice Change Guidelines 
 Selection of Best Practice Guidelines 
 The General Best Practice Guidelines for Immunization was established by the 
Advisory Committee on Immunization Practices (ACIP). There are 10 documents that 
include specific recommendations of vaccines in this clinical practice guideline (CPG). 
This guideline is updated every three to five years by both review and analysis of current 
scientific data and expert opinions of different health-care providers and officials from 
public health which are members of the General Recommendations Work Group 
(GRWG). Several groups of healthcare are professionals involved including family 
practice, pediatrics, and pharmacy. To appraise the quality of this CPG the AGREE II 
instrument was used (AGREE Next Steps Consortium, 2013). The Grading of 
Recommendations Assessment Development and Evaluation (GRADE) system was used 
to rate the CPG. This CPG was found to have high quality of evidence and research 
including key evidence and guidelines to defend the strong strength of the 









recommended by the CDC, this paper will focus on the guidelines pertaining to the HPV 
vaccine.  
Table 2: 












age for this 
dose 
Minimum 






interval to next 
dose 
HPV Two Dose Series (If starting the vaccine at age 9 through  
14 years old) 
HPV – 
1  
11-12 years  9 years 6 months 5 months 
HPV – 
2 
11-12 years 9 years + 5 
months 
- - 
HPV Three Dose Series (Typically given at age 15 and older)  
HPV – 
1  
11-12 years  9 years  1-2 months 4 weeks 
HPV – 
2 
11-12 years 9 years (+4 
weeks) 





9 years (+5 
months) 
- - 





1. Contraindications include any severe allergic reaction or 
anaphylaxis after a previous dose of the HPV vaccine or to 












2. Conditions commonly mistaken as contraindications or 
precautions for all general vaccines, including HPV, and 
this includes any acute mild illness that does or doesn’t 
produce a fever, patient does not have a previous physical 
exam in a well-appearing person, if a person is on 
antibiotics, mending phase of an illness, recurrent exposure 
to an infectious disease, history of other non-vaccine 
allergies, penicillin allergy. 
3. Common mistaken contraindications and precautions 
specific for the HPV vaccine include: previous abnormal 
papanicolaou test, breast feeding, history of genital warts, 
a current HPV infection, or immunosuppressed.  









1. If an adverse reaction occurs with a vaccine this is 
reported in the Vaccine Adverse Event Reporting 
System (VAERS). In 2005, the HPV, MenACWY, and 
Tdap vaccines were flagged in this system, due to the 
vaccines causing syncope. If syncope occurred these 
adolescents were at in increased risk for injuries due to 
the syncope including skull fractures and cerebral 
hemorrhages. Between January 1, 2005 to July 31, 2007 









of those obtained secondary injuries. Approximately 
76% of those reports were categorized as adolescents. 
Within 15 minutes of vaccine administration 80% of the 
syncope episodes happened among all age groups. This 
has encouraged providers to be proactive when giving 
vaccines to prevent injuries due to dizziness or syncope. 
When giving the vaccine the patient should be sitting or 
lying down and the patient should be observed for 15 
minutes after administration, if symptoms develop the 
patient should be kept until all symptoms resolve. 
2. Serious allergic reactions are rare occurring one per 
million dose for many different vaccines. Airway 
management equipment and epinephrine should be 
available to be used immediately if a reaction occurs. 
The best practice to avoid allergic reactions is to obtain 
a thorough history.  







1. The HPV vaccine is a 0.5 ml dose and to be given 
intramuscularly.  


















1. The HPV vaccine is to be stored at a temperature of 2-8 
degrees Celsius, the vaccine is not to be frozen and is not 
to be diluted.  






1. Research does not recommend pregnant women receive the 
vaccine even though it is not a live virus and no evidence 
exists showing the vaccine to be harmful to the fetus.  







1. The HPV vaccine is said to be critical for adolescents and 
young adults in general due to a higher risk or increasing 
risk of the HPV infection. Vaccination of the HPV is 
essential in preventing disease.  
2. To improve vaccination rates among children, adolescents, 
and adults, recommendations of interventions were 
researched. Community education alone had insufficient 
evidence on whether it was effective and community-based 
interventions implemented in combination was 









(Quality of Evidence – High, Strength of Recommendation, 
Strong) 
 Reproduced from Ezeanolue, Harriman, Hunter, Kroger, & Pellegrini, C., 
2017. 
Lack of Information 
Lack of information can be a contributing factor to not receiving the HPV 
vaccine. Research has identified that the lack of information regarding HPV and 
the HPV vaccine exist. College-aged students might already know what HPV and 
the HPV vaccine, but others may not recognize these topics.  
According to Lai, et al., (2016) a 21-item survey was used to assess 228 
African American, African refugee, Hispanic/Latino, American Indian, and 
Native American from community organizations of their knowledge of the HPV 
vaccine. The majority of the respondents were age 35-50, female, and married, or 
living as married. Almost 67% of the surveys participants were immigrants and 
over half had health insurance. Approximately 46.5% of the respondents had 
heard of the HPV vaccine. The study found that people less  acculturated were 
more likely to learn about HPV through personal networks, such as friends, 
family, and church. Participants born in the US were more likely to learn  about 
the HPV vaccine through media such as social networks, billboards, and 
television. The study found that healthcare system sources were the most 
preferred source of HPV information. The participant had an increased accuracy 
of knowledge of the HPV vaccine if the healthcare provider educated the patient 









education that could provide an increased uptake of the HPV vaccine (Lai, et al. , 
2016).  
According to Macarthur (2017), a study of 755 college students from a 
large midwestern university were asked about their health beliefs, and if this 
related to whether they had received the HPV vaccine. The study was conducted 
between November 2012 and January 2013. The study concluded that the belief 
in one’s health care provider is directly linked to an uptake in the intentions of 
the HPV vaccine 
Lack of Education 
Education regarding HPV and the HPV vaccine can be overwhelming. 
Health care providers are responsible for providing accurate education to 
patients. Studies indicate that a health care providers recommendation influences 
the HPV vaccine uptake.  
A qualitative study conducted by Ogunbajo, Hansen, Noth, Okoloko, & 
Niccolai, (2016) researched knowledge of HPV and the HPV vaccine from the 
parents and legal guardians of children aged 10-18 from lower incomes and 
ethnic minorities. Many participants felt the HPV vaccine was no different than 
any other vaccine in that they prevent disease, was administered the same, and 
believe in the recommendation of the health care provider. The fact that HPV 
prevents cancer, which was viewed as a serious disease, was one of the greatest 
benefits. Mixed opinions were stated from the parents due to the mode of sexual 
transmission for HPV. Most guardians and/or parents had a positive view of the 









of the HPV vaccine in this age group is bundling the vaccine with the TDAP and 
meningitis vaccine or school entry requirements.  
A study conducted by Kornides, Calo, Heisler-MacKinnon, and Gilkey 
(2017), studied U.S. providers and clinic staff experiences of the 9 -valent HPV 
vaccine, which is the current HPV vaccine administered. In this study of 211 
participants the quadrivalent vaccine was used. When comparing the previous 
quadrivalent vaccine to the 9-valent vaccine providers stated they would strongly 
recommend (66%) or more strongly (33%) recommend the 9-valent over the 
quadrivalent. At least 61% of the study reported no concerns with the up-to-date 
HPV vaccine but 29% reported parental hesitancy, 17% insurance coverage 
issues, and 10% other issues. This study reported provider recommendation was 
the most important facilitator in obtaining the HPV vaccine. Parental concerns 
were not investigated which could be used by staff to educate further. Education 
of terminology was reviewed with providers regarding vaccines to not use words 
such as “new” with patients, for example, there is a new vaccine for HPV.  
A survey of parents of adolescents regarding parental willingness of the 
HPV vaccine administration was conducted by Erves, Mayo-Gamble, Hull, Duke, 
and Miller (2017). In the study 47% of parents were willing to let their 
adolescent participate in the HPV vaccine clinical trial. There was a total of 
30.7% African American and 48.3% Caucasian asked to participate. In total 
African Americans had a lower awareness of the HPV vaccine but no lower 
intentions to get the HPV vaccine. The child’s age, perceived advantages of the 









the clinical trial information with ease was positively associated with parental 
willingness. Education was found to have a positive impact on the uptake of the 
HPV vaccine in this study.  
An observational study conducted by Wilson, et al. (2016) examined 
factors related to HPV vaccine uptake of 325 18-26-year-old females in Utah. 
The results of the study stated 204 (62.8%) had received a single HPV vaccine: 
of those that received at least one dose of the HPV vaccine, 159 (48.9%) 
completed the HPV vaccine series. Lower age, not currently married, not 
practicing an organized religion, education on how HPV spreads, awareness of 
the relationship between HPV and cervical cancer, confidence in vaccine 
prevention, doctor recommendation and how influential the doctor’s 
recommendation was were all factors contributed to completion of the HPV 
vaccine series as well.   
Beliefs 
The HPV vaccine can have a stigma due to HPV being caused by 
unprotected, vaginal, anal, and oral sex. Even if intercourse only occurs with one 
person, the other person may have had other contacts before which can put 
anyone at risk that has unprotected sex with this person. Males are not screened 
for HPV and many times have no symptoms of a current HPV infection.  
According to Franco, Mazzucca, Padek, and Brownson (2019) the highest 
completion of the HPV vaccine series is the District of Columbia with 62% and 
Rhode Island with 70.8%. The states with the lowest completion rates are Texas, 









completion rates are known to be more conservative and religious states than 
those with higher completion rates. In these states there were no stricter 
education policies or vaccine exemptions. The study included 20,495 adolescents 
from all 50 United States. The study concluded that many factors contribute to 
the HPV vaccine uptake and completion including political beliefs, education 
through sex education, religion, and gender. The clinic is the most important 
location and the preferred source for information on deciding to complete the 
HPV vaccines. The television was the second preferred source, followed by 
schools and pamphlets.  
A study focusing on factors associated with school nurses’ HPV vaccine 
attitudes for school-aged youth by Rosen, DiClemente, Shepard, Wilson, and 
Fehr (2017) had 413 participants from the National Association of School 
Nurses’ membership that completed a web-based survey. The study revealed that 
positive attitudes toward the HPV vaccine is associated with a higher HPV and 
HPV vaccine knowledge. This study reiterated additional education to be given 
about the HPV vaccine and HPV so that these nurses could relay the accurate 
information to parents to increase the uptake of the HPV vaccine.  
Lack of Access 
 Access to the HPV vaccine can be an issue due to cost and availability. 
The HPV vaccine can be expensive without insurance, which can be a barrier to 
vaccination. If the patient does not have transportation or time to receive the 









A qualitative study conducted by Roncancio, et. al., (2016) of 51 in-depth 
interviews of Hispanic mothers of adolescents of the product, price, place, and 
promotion of the HPV vaccine. The study found that vaccine reminders, the fact 
that the HPV vaccine prevents illness and disease were the factors in those that 
completed the vaccine series. Those mothers that children had completed the 
vaccine series had no barriers. Mothers whose children had received the first 
dose of the HPV vaccine but not the 2nd or 3rd dose stated cost and lack of health 
insurance as barriers.  
 A study conducted by Britt and Britt (2016) looked at the rural healthcare 
needs related to the HPV vaccine. The study examined students from a rural and 
medically underserved campus with 327 participants. The HPV vaccine uptake 
was as follows: 48.3% no vaccine uptake, 38.8% reports one immunization, 8.4% 
reports two shots, and 4.5% reporting completion of the HPV vaccine series. The 
study found no significant relationship between, intent,  gender, beliefs, and 
attitudes of the HPV vaccine. Gender was a predictor of vaccine uptake, the 
research recommends that males receive education that state they can receive the 
HPV vaccine, as it is known females can receive the HPV vaccine. The intent t o 
complete the vaccine series is most linked to a doctor’s recommendation. 
Barriers stated in this study were perceived susceptibility of HPV and cost. 
Increased vaccination rates were a result from positive attitudes of the HPV 
vaccine. The study recommended rural college campuses need to be targeted to 
complete the HPV vaccine. Creating a positive attitude of the HPV vaccine can 










 There is a limited amount of research conducted in the United States 
specifically related to the HPV vaccine. More research should be conducted on 
these barriers to examine them further. Several of the research articles found 
only used a sample of females. The HPV vaccine pertains to all genders. No 
significant conflicting data was found. Many of the articles stressed belief in the 
health care providers recommendation, education about HPV and the HPV 
vaccine, and access to the vaccine.   
Summary 
 Vaccination compliance is a gray area to the public. It is important for 
healthcare providers to do research and relay that information to patients. 
Existence of vaccine preventable diseases and cancers prove that there is  still 
room for improvement. Assessing for vaccine compliance is important at every 
visit with every patient.  
There are many questions that are not answered from the literature review 
including what the views of HPV in Kansas are, what their concerns are for 
vaccinating with the HPV vaccine, and if these views differ in every state? A 
study being conducted of assessing HPV vaccine uptake, HPV vaccine, and HPV 
education at a rural college campus and what variables can be changed to 



























This chapter will review the design for this scholarly project. The sample group, 
instrument used, and statistical analysis will be discussed. A two-part study was 
performed to evaluate whether there will be an increase in knowledge post-education of 
HPV. A quantitative study was used to evaluate knowledge with a pretest and posttest. 
Several tests were used to evaluate responses including an independent sample t-test, a 
paired sample t-test, and a mean and standard deviations. Quantitative data generalizes 
numerical data across a group of people that can help explain an occurrence. The research 
ultimately supports or rejects the occurrence. This data can be presented into graphs and 
tables (McLeod, 2019).  
A descriptive research approach was used to study knowledge of HPV and the 
HPV vaccine among college students. The study educated 58 students on facts and 
evidence-based clinical practice guidelines regarding HPV and the HPV vaccine. The 
education was provided in the Pittsburg State University Fall 2019 Health Promotion 
class. The pretest included demographics, HPV experiences of study participants, and a 
questionnaire with 18 true/false questions.  
Research of HPV and the HPV vaccine was obtained and studied by the 









developed from a previous study conducted by Salima Kasymova, Sayward Harrison, & 
Caroline Pasca, (2019), based on research found and objectives of this study. Approval 
was given to use previous use tool by the developer, Sayward Harrison. A pretest and 
posttest was administered in this study that was used from a previous study conducted by 
Salima Kasymova, Sayward Harrison, and Caroline Pascal and education was presented 
to the audience in the form of a PowerPoint. The pretest was complete prior to the 
educational presentation and the posttest was completed after the educational 
presentation. Analysis of the data obtained was reviewed by the researcher. This 
researcher and statistician ultimately interpreted the data collected. The data interpreted is 




An educational presentation was designed for college students enrolled in the 






















obtained after evidence-based practice research was presented to the audience. The 
knowledge presented would expand on current knowledge with evidence-based practice. 
The study focused on the following research questions:  
1. What are the demographics (gender and age) of the respondents? 
2. Will students have heard of the HPV vaccine pre-education? 
3. Will students have heard of HPV pre-education? 
4. What is the respondent’s HPV knowledge pre-education? 
5. Has a healthcare provider recommended the HPV vaccine to the respondent? 
6. Has the respondent received at least one dose of the HPV vaccine series?  
7. What is the respondent’s HPV knowledge post-education? 
8. Did education increase the knowledge of HPV post-education?   
Settings and Participants 
The setting of this study was at the Pittsburg State University Irene Ransom 
Bradley School of Nursing lecture hall. The educational presentation was conducted on 
December 4th, 2019.  The population of this study included students enrolled in the 
Health Promotion class in the Fall of 2019 at Pittsburg State University. All participants 
were eligible to participate in the pretest and posttest and the presentation, consent was 
implied with the completion of the pretest. The participants were all over the age of 18.  
Recruitment 
The target population recruited for this presentation and survey is the Fall 
2019 Health Promotion class at Pittsburg State University. This class  consisted 
of 58 students includes pre-nursing, nursing, and health majors. The presentation 









Participation was voluntary in nature; students were given the opportunity to 
leave class before the presentation began. No compensation, or extra credit was 
provided to the participants. Full participation in this study include completion 
of the pretest and posttest and being present for the educational presentation.   
Inclusion/Exclusion Criteria 
 Inclusion criteria for the pretest and posttest and presentation included all 
students enrolled in the Health Promotion class. The participant must be over the 
age 18. No other inclusion was used in this study. The specific exclusions for 
this study include being under the age of 18, not enrolled in the Pittsburg State 
University Health Promotion class, and not giving consent.  
Protection of Human Subjects 
The checklist for human subjects was reviewed by the researcher and it was 
deemed that the study followed the Pittsburg State University human subjects and 
departmental guidelines for an exempt study. The process of the study was reviewed by 
the Human Subject Committee at Pittsburg State University. The population for the 
educational presentation was adult students over the age 18. The population does not 
contain any children, prisoners, or any specific people of race, religion, or ethnicity. 
There was no techniques that caused harassment or discomfort or deception of 
participants. Confidentiality was maintained throughout the study through numbering the 
pretest and posttest along with specific questions answered at the beginning of the pretest 
and posttest. There were no risks involved with participation in this scholarly project. 









could place them at risk of civil or criminal liability or have any damage to their 
reputation, employability, or school standing.  
Data was obtained from participants volunteering for the study. Completion of the 
pretest and posttest ensured consent for the study. Confidentiality was maintained 
throughout the study and the information obtained include four identifying factors of the 
participants: the first initial of mother’s name, first initial of Mother’s maiden name, first 
initial of the town they were born in, and first initial of their middle name, the surveys 
were numbered. After the surveys were complete, they were placed in a locked box only 
accessible to the researcher. At completion of the scholarly project the test were 
shredded.  
Ethical Considerations 
There are few ethical considerations for this study. This descriptive study design 
has a pretest and posttest. Any ethical considerations focused around the test 
development and the answers provided. Consistent anonymity is the first ethical concern. 
The information obtained from the surveys remained confidential and was stored without 
identifiers so participants cannot be identified by any way or anyone. Participants 
truthfully answering surveys is the second ethical concern. Data can be skewed if 
someone intentionally provides false data. The test used is from a previous research 
project and validity and reliability has been proven.  
Instrument  
The pretest and posttests were conducted by using pen and paper by the 
participants to gather quantitative data. There was three sections of the survey. The first 









third section assessed HPV knowledge. The posttest included only the third section along 
with a section that assessed impact of the education provided.  The test contained yes/no 
and true/false responses. The pretest included demographics, HPV experiences, and 18 
HPV knowledge questions. The posttest included the 18 HPV knowledge questions and a 
question that evaluates the impact of the education provided. The tool used is consistent 
with evidence-based practice.  
Content Validity 
The survey tool accurately reflects students’ knowledge of evidence-based 
practice guidelines of HPV and the HPV vaccine. The tool is from a previous peer-
reviewed research study by Salima Kasymova, Sayward Harrison, and Caroline Pascal 
(2019). This tool yielded a strong internal consistency (=.79). Contact was made with 
Dr. Sayward Harrison regarding reuse of the HPV survey and this was granted. Dr. Greg 
Belcher, Ph. D., Director of the Kansas Center for Career and Technical Education at 
Pittsburg State University, a committee member of this project reviewed validity of the 
survey.  
Operational Definitions 
The following operational definitions are used in the purpose of this project: 
1. Human papillomavirus (HPV) – A kind of virus that can cause abnormal 
tissue growth and other changes to cells. Long term infection with certain 
types of human papillomavirus or HPV can cause cervical cancer and can 
play a role in some other types of cancer, such as anal, vaginal, vulvar, 









2. Immunization – the process of obtaining protection though vaccination 
from diseases, also used interchangeably with vaccination, inoculation, or 
vaccination uptake (CDC, 2018e)  
3. Vaccination – receiving a vaccine that will allow the body to gain 
immunity against a specific disease; inoculation  
4. Vaccine – “A product that stimulates a person’s immune system to 
produce immunity to a specific disease, protecting the person from that 
disease. Vaccines are usually administered through needle injections but 
can also be administered by mouth or sprayed into the nose (CDC, 
2018e).” 
Procedure 
This project contained an educational presentation, a pretest, and a posttest. The 
participants were present for class in the Fall 2019 Health Promotion class at Pittsburg 
State University. Once seated the study was explained and students had the opportunity to 
dismiss themselves if desired.  The participants was then handed a packet. The packet 
contained both the pretest and the posttest. The participants were instructed to not open 
the envelope until instructed, until the presentation was explained and questions 
answered. The participants were instructed to take the pretest out of the packet.  The 
pretest contained demographics, HPV experiences, and HPV knowledge test. The pretest 
was completed and placed in the locked box, then the educational PowerPoint was 
presented to the class. The presentation was explained, and questions were answered. The 
educational program was presented and lasted approximately 20 minutes. There was an 









from the packet. The posttest contained the same HPV knowledge survey and possible 
future actions from the presentation. Once completed the posttest was secured in the 
locked box. The surveys were matched by number and specific responses on the surveys 
and data was logged into SPSS. All data was reviewed and is accurate to the researcher.  
Data Collection  
The pretest contained demographic data. This ensured inclusion of the group and 
characterized the participant by gender. The data was collected kept confidential online 
and only accessed by the researcher. The results of the project is published in Chapter IV 
of the project without any identifying data. At the end of the project the tests were 
shredded.  
The data was entered and analyzed using SPSS and formulations calculated. A 
probability level of p<0.05 is considered statistically significant. T-tests were conducted 
on the results of the pretest and posttest. A comparison of the pretest and posttest was 
conducted.  
Outcome Data 
Based on the analysis of the pretest and posttest the following outcomes were 
generated by the SPSS program for the following research questions.   
1. What are the demographics (gender and age) of the respondents? 
2. Will students have heard of the HPV vaccine pre-education? 
3. Will students have heard of HPV pre-education? 
4. What is the respondent’s HPV knowledge pre-education? 
5. Has a healthcare provider recommended the HPV vaccine to the respondent? 









7. What is the respondent’s HPV knowledge post-education? 
8. Did education increase the knowledge of HPV post-education? 
Outcomes 
 Evaluation measures linked to objectives. Objectives in the logic model was 
used for evaluation measures. The project contained an educational presentation with a 
pretest and posttest to evaluate knowledge of evidence-based research of HPV and the 
HPV vaccine. The outcomes that was evaluated include increasing HPV and HPV 
vaccine knowledge, assessing pretest and posttest data, and evaluating if data encouraged 
vaccine uptake if the participant had not received the HPV vaccine. If correct answers are 
answered on the posttest a positive outcome will be achieved. Short-term outcomes that 
was accomplished include increased knowledge of HPV and the HPV vaccine after the 
education presentation. Medium-term outcomes include an increase of vaccine 
knowledge in students and the general public. Long-term outcomes include that there will 
be increased rates of HPV vaccination, which will take years to evaluate. Further research 
should be conducted at that time.  
 The posttest was given directly after the presentation to keep the information 
relevant and no other information was obtained by the participants. The data obtained 
from the pretest and posttest was assessed to evaluate if an increase of knowledge 
occurred.  
 Instrument Linked to Measures and Objectives. This measurement tool 
included a pretest and posttest after an educational presentation over evidence-based 
research of HPV and the HPV vaccine. The instrument included an 18 HPV knowledge 









same questions as the pretest. A total score of correct answers was tabulated for each 
participant. The test had a variety of questions with the HPV knowledge questionnaire 
being all true or false. Spontaneous responses were not allowed on the test. The test 
questions validated evidence-based research knowledge of HPV and the HPV vaccine. 
The table below represents questions answered and intended outcomes of the project.  
Table 3: 
Objectives, Measurements, and Outcomes 







ensure inclusion of 










submit if they have 




correctly answer if 
they have heard of 
the HPV vaccine 
pre-education.  
Mean and standard 
deviation  
Participants will 
have heard of HPV 
pre-education.  
Participants will 
submit if they have 
heard of the HPV 
pre-education. 
Participants will 
correctly answer if 
they have heard of 
the HPV pre-
education.  











have knowledge of 
HPV pre-education.  
Participants will 
submit correct 











have had a health 
care provider 
recommend the 
HPV vaccine.  
Participants will 
have an increase of 
health care provider 
recommend the 
HPV vaccine.  
Participants will 
submit whether a 
healthcare provider 
has recommended 
the HPV vaccine.  
Mean and standard 
deviation  
Participant will 
have received once 
dose of the HPV 
vaccine.  
Participants will 
receive the HPV 
vaccine.  
Participants will 
submit whether that 
have received the 
HPV vaccine.  
T-test 
Participants will 
have knowledge of 
HPV post 
education.   
Participants will 
have an increase of 
HPV knowledge 
post education.  
Participants will 
correctly answer 




knowledge of HPV 




knowledge of HPV 
post education by 
Participants will 
submit correct 
answers on the post 












on the post test.  
 
Methods of Analysis for Measurement 
 To analyze the data collected the data was transferred into SPSS. The probability 
level accepted is p<0.05. If less than 0.05 occurs then the outcome occurred by chance 
and not because of the educational presentation. Results occurring as a result of the 
education indicated a 95% confidence interval. To compare the pretest and posttest t-tests 
were used.  
 Each question was worth one point. The pretest and posttest was used to evaluate 
knowledge gained from the educational presentation of evidence-based research of HPV 
and the HPV vaccine. The HPV knowledge questions were all true/false answers.  
Sustainability 
 There is no specific criteria for sustainability. An effective way to increase 
knowledge of HPV and the HPV vaccine is through education. Sustainability can be 
ensured by education of evidence-based research of HPV and the HPV vaccine to health 
care providers. There are several different avenues that education can be provided to the 
public including through public schools, public health fairs, and through local doctors’ 
offices. Planning and implementation will ensure sustainability of evidence-based 
research of HPV and the HPV vaccine.   
Summary  
 Evidence based research of the HPV and the HPV vaccine was presented as an 









completed prior to the education and a posttest was be obtained after the education. The 
survey included a questionnaire with 18 true/false questions. The results of this project 
















































 A descriptive research design was utilized in this scholarly project. This data was 
collected to determine if there would be an increase in knowledge about HPV and the 
HPV vaccine in college students in the Health Promotion class at Pittsburg State 
University after the students were provided with an educational PowerPoint lecture over 
HPV and the HPV vaccine. The data in this scholarly project was collected by a pretest, 
followed by an informative PowerPoint lecture concerning HPV and the HPV vaccine 
education and the posttest was collected. The sample included 58 students. The pretest 
contained demographic information and a HPV questionnaire of 18 questions. An 
educational PowerPoint was then presented. A posttest was them completed by the 
students that included the same 18 HPV questionnaire, along with inquiring if they intent 
to receive the HPV vaccination post education. The pretest contained demographic 
questions including gender, if they have ever heard of HPV and the HPV vaccine, and if a 
provider has ever recommended the HPV vaccine to them. The test also asked if they 
have obtained the HPV vaccine and 18 questions about HPV and the HPV vaccine.  
Demographic Data  
 The demographic data collected from respondents included gender, of the 









respondents were female (93.1%). The study found 100% of the participants had heard of 
the HPV vaccine pre-education (n=58).  Almost all of the participants have heard of HPV 
pre-education, 96.6% of students had heard of HPV (n=56) and 3.4% of students had not 
heard of HPV pre-education (n=2). Of the participants, 70.7% had the HPV vaccine 
recommended to them (n=41), 27.6% had not had the HPV vaccine recommended to 
them (n=16), and 1.7% of participants did not know if they have had the HPV vaccine 
recommended to them (n=1). The participants were asked if they had received at least 
one dose of the HPV vaccine series, 75.9% of students stated they had received at least 
one dose (n=44), 15.5% of students had not received the HPV vaccine (n=9), and 8.5% of 
respondents did not know if they had received the HPV vaccine (n=5).  
Table 4: 
Gender of Participants 
 Frequency Percent 
 Male 4 6.9 
Female 54 93.1 
Total 58 100.0 
 
Table 5:  
Has the Respondent Ever Heard of the HPV vaccine? 
 Frequency Percent 












Table 6:  
Ever Heard of HPV Pre-education? 
 Frequency Percent 
 Yes 56 96.6 
No 2 3.4 
Total 58 100.0 
 
Table 7: 
Has a Healthcare Provider Recommended the HPV Vaccine to the Respondent?  
 Frequency Percent 
 Yes 41 70.7 
No 16 27.6 
Don’t Know 1 1.7 
Total 58 100.0 
 
Table 8:  
Has the Respondent Received at Least One Dose of the HPV Vaccine Series?  
 Frequency Percent 
 Yes 44 75.9 
No 9 15.5 
Don’t Know 5 8.6 
Total 58 100.0 
 
Pretest and Posttest  
 All participants were given a pretest prior to the education and posttest following 
the education. The tests were given to the participants in a large yellow envelope and 
grouped by a number code in the right-hand corner along with 4 anonymous answers at 
the top of each test. Both tests contained the same 18 HPV questionnaire that were true, 









questionnaire was from a previous study conducted in South Carolina by Salima 
Kasymova, Sayward E Harrison, and Caroline Pascal in 2019. For each correct answer on 
the HPV questionnaire a point was received, if a person answered every question correct, 
they would receive 18 points.  
Results of the Study  
 The study concluded with statistical significance (p<0.05) that the education 
provided did increase the knowledge of the students with evidence-based facts on HPV. 
The posttest scores were higher after the education was presented. All pretest and posttest 
were completed entirely. The mean score of the pretest was 11.79 questions correct out of 
18, with a standard deviation of 2.634. The mean score of the posttest was 16.47 
questions out of 18, with a standard deviation of 1.513. This concluded that there was a 
difference between knowledge of HPV on the pretest and posttest. All participants had an 
increase in posttest sores after the education was presented (n=58).  After the education 
there were seven participants (50%) that reported they intended to receive the HPV 
vaccination. 
 
Table 9:  
HPV Knowledge on Pretest and Posttest 
 Pretest Score Posttest score 
Mean 11.79 16.47 











Table 10:  
The Difference in Knowledge of HPV on the Pretest and Posttest 
 Mean SD N 
Pair 1 Pretest Score 11.79 2.634 58 
Posttest score 
16.47 1.513 58 
 





Mean    
Pair 
1 
Pretest Score - 
Posttest score 
-4.672 2.793 .367 -12.739 57 .000 
 
 
Individual Comparison of Pretest and Posttest 
 On the pretest the most missed question was question number six, most genital 
infections do not clear up on their own (false) with 79.3 percent of the students choosing 
the incorrect answer of true (n=46). Followed by question four, there is a test to 
commonly test males for HPV (false), and question 10, the HPV infection can cause 
genital herpes (false). Both of these questions had 72.4% of the students answer them 
incorrectly by stating they were false when in fact they are true (n=42). Question 18, 
nearly all sexually active men and women will contract HPV at some point (true), had 
68.9% of students answer this question incorrectly stating that it was false (n=40). The 
questions that had the most answered correctly was question 11, certain types of HPV can 
lead to cervical cancer in women (true), and question 12, HPV can lay dormant in the 
body for years without symptoms (true) with 98.2% of students answering these two 









 On the posttest there are several questions with 100% of students answering the 
question correctly, questions 1, 5, 8, 11, 12, and 13 (n=0). Question one is, HPV is a 
sexually transmitted infection (true), question five is an abnormal Pap smear may indicate 
that a woman has HPV (true), question eight is HPV is not a very common virus (false), 
question 11 is certain types of HPV can lead to cervical cancer in women (true), question 
12 is HPV can lay dormant in the body for years without symptoms (true), and question 
13, a person’s chances of getting HPV increase with the number of sexual partners they 
have (true). The most missed question on the posttest was question 15, genital warts can 
cause cervical cancer (false), with 37.9% of students answering this question incorrectly 
(n=22).  
 Question four, there is a screening that is commonly used to test males for HPV 
(false) and question 18 (nearly all sexually active men and women will contract HPV at 
some point (true) had the biggest improvement of correct answers from the pretest to the 
posttest, with a 35 point difference on question four and a 34 point difference on question 
















 Chapter IV reviewed the statistical analysis of this project. A positive outcome of 
this project includes an increase knowledge about HPV and the HPV vaccine after the 
education was presented to this group of participants. Before the education was presented 






















education the score increased to 16, showing improvement.  This study concluded that 
even though most students were recommended the HPV vaccine there was still a 
knowledge gap about HPV and the HPV vaccine. The findings of this study confirm the 
need for more education about HPV and the HPV vaccine amongst college students to 







































Summary, Conclusions, Recommendations 
 
 
 This study included an educational presentation about HPV and the HPV vaccine 
following evidence-based facts and guidelines to evaluate overall knowledge of HPV. 
The study assessed students’ knowledge after an educational presentation. A pretest was 
taken before any education and a posttest was given immediately after the education was 
presented. The project also evaluated if students had received the HPV vaccine or have 
had this vaccine recommended to them by a provider.  
Relationships of Outcomes to Research  
 This study found that 75.9% of the participants had at least one dose of the HPV 
vaccine. This is still below the Healthy People 2020 goal of 80% of the public being 
vaccinated with the HPV vaccine. In a previous study by Salima Kasymova, Sayward 
Harrison, and Caroline Pascal (2019) the rate of HPV vaccination was 64.1% and 72.7% 
of participants reported a provider recommended the HPV vaccine. In this study, 70.7% 
of the participants reported a provider recommended the HPV vaccine to them. This is an 
opposite finding of this study that had a lower number of vaccinated participants and a 
higher number that had had the HPV vaccine recommended to them. More respondents in 
this project obtained this vaccine without recommendation from a provider than the 









standard deviation of 3.7. This study had a mean total score of 11.79 and a standard 
deviation of 2.634 on the pretest. One of the most missed questions on both of these 
studies was whether there is a screening commonly used to treat males and if HPV 
infections generally clear up on their own. There was also confusion on this study and the 
previous study on the distinction of HPV and genital herpes. Both studies found the 
majority of participants were aware of HPV. This study confirmed that more education is 
needed on HPV to the public including college students.  
Observations 
 Many different observations can be made from the data gathered on the pretest 
and posttest. The information gathered can be used to compare with previous studies and 
research. Even though one of the previous studies was done with a larger sample, similar 
data is found in this smaller study. A knowledge gap exists of HPV and the HPV vaccine 
with an average of the participants missing at least seven out of 18 questions. Even 
though the number of participants that reported obtaining at least one dose of the HPV 
vaccine is below the healthy people 2020 goal it was higher than previous studies at 
75.9%. The number of participants that have had the HPV vaccine recommended to them 
was less than previous studies. This could possibly mean the participant did not have a 
providers recommendation before receiving the HPV vaccine. After the education the 
posttest results improved with the average participant missing less than two questions.  
Evaluation of Theoretical Framework 
 The theoretical framework applied to this project was the Health Belief Model 
(HBM). Following this theory, the increase of HPV knowledge will increase HPV 









about HPV and the possible risk of HPV to the participant. Through education the 
participant learned they could avoid possible outcomes of HPV by obtaining the HPV 
vaccine. Because of this education there were seven participants that reported they would 
obtain the HPV vaccine. This follows the HBM. The education provided to the 
participants followed the six concepts. The participants were educated on the research 
regarding acquiring HPV and the consequences of HPV. The participants were educated 
on the HPV vaccine would protect them from further HPV strains. The participants were 
educated on barriers to prevent HPV infections. Evidence based practice research and 
guidelines were presented to the participants to assure them the HPV vaccine will protect 
them against HPV.  
Evaluation of Logic Model 
 This study measured the participants knowledge of HPV before and after an 
educational presentation presented to the fall 2019 health promotion undergraduate 
students at Pittsburg State University. The evaluated outcomes measured were knowledge 
of HPV and intention of the HPV vaccination after the presentation. There is an 
assumption that there will be an increase of HPV and HPV vaccine knowledge in the 
students enrolled at Pittsburg State University after this presentation.  
 Positive outcomes of this study include an increase of HPV and HPV vaccine 
knowledge after the presentation as indicated by pretest and posttest scores. Also, several 
participants reporting wanting to obtain the HPV vaccine to protect them from HPV. The 
project supported the logic model in all outcomes, short and medium. Long term 










 There are several limitations to this study. One limitation is actual vaccination 
records were not obtained and self-reported. This could lead to a false number of 
vaccinated or unvaccinated participants. There was no follow-up to see if the participants 
intending to get the HPV vaccine actually received the HPV vaccine. The pretest and 
posttest was also self-reporting and it is assumed the participant answered the questions 
honestly and to the best of their knowledge on the surveys. The participant had both the 
pretest and posttest, it is assumed that directions were followed, and the pretest was 
completed and placed in a yellow envelope and no answers were changed after the 
presentation. The majority of the study participants were female, which leaves an unequal 
proportion of genders in this study. This study also contains many students involved in 
health-related majors which may have contributed to previous knowledge of HPV and the 
HPV vaccine. Long term outcomes could not be evaluated due to time constraints.  
Implications for Future Projects 
 Limitations stated above should be addressed for future studies. It would be 
appropriate to obtain immunization records of the sample to gain an accurate percentage 
of HPV vaccination. The researcher could easily verify if the participant has had the 
doses of the HPV vaccine to be fully covered. A follow-up in two months would be 
recommended for participants intending to get the HPV vaccine. There could also be 
another follow-up in a year to evaluate if they have talked or shared any information of 
HPV to anyone since the education was provided to evaluate an increase of HPV in the 
general public. Future projects with equal amount of male and female participants would 
evaluate if gender specific differences are noted. This project could be repeated in a non-









Implications for Practice/Health Policy/Education 
 The goal of this project was to increase knowledge of HPV and the HPV vaccine 
among college students leading to an increase of HPV vaccination rates. Information of 
HPV and the HPV vaccine can be utilized by healthcare providers, future healthcare 
providers, and the general public. Results of this project contains important information 
to health care providers, policy makers, and the general public. This project reinforced 
that the Healthy People 2020 goal of 80% of HPV vaccination uptake is still not being 
met.  
Conclusion 
 This project provided participants with evidence-based research regarding HPV 
and the HPV vaccine. Studies show there is lack of information that contributes to the 
low HPV vaccine uptake. The knowledge gained in this project increased awareness of 
HPV and the HPV vaccine. It is possible many of these participants will have careers 
healthcare and influence in the uptake of the HPV vaccine. As evidenced by results of 
this project more education is needed among college students about HPV and the HPV 
vaccine to prevent the spread of HPV and improve the uptake of the HPV vaccine. This 
can prevent diseases caused by HPV and even cancer. To stop these outcomes evidence-
based research of HPV and the HPV vaccine should be shared, among the community 














AGREE Next Steps Consortium (2013).  The AGREE II instrument [Electronic version].  
 Retrieved from http://www.agreetrust.org. 
Britt, R. K., & Britt, B. C. (2016). The need to develop health campaigns for obtaining 
 the HPV vaccine in rural and medically-underserved college campuses. Education 
 & Health, 34(3), 74–78. Retrieved from https://search-ebscohost-
 com.library.pittstate.edu/login.aspx?direct=true&AuthType=ip&db=rzh&AN=11
 8948346&site=ehost-live 
Centers for Disease Control and Prevention. (2018a). About CDC 24-7. Retrieved from: 
 https://www.cdc.gov/about/history/index.html 
Centers for Disease Control and Prevention. (2018b). HPV coverage data.  Retrieved 
 from: https://www.cdc.gov/hpv/hcp/vacc-coverage/index.html  
Centers for Disease Control and Prevention (2018c). HPV vaccines. Retrieved from: 
 https://www.cdc.gov/hpv/parents/vaccine.html 
Centers for Disease Control and Prevention. (2018d). Vaccine safety. Retrieved from:  
 https://www.cdc.gov/vaccinesafety/vaccines/hpv-vaccine.html 
Centers for Disease Control and Prevention. (2018e). Vaccines & immunizations. 
 Retrieved from: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm 
Centers for Disease Control and Prevention. (2019). Human papillomavirus. Retrieved 
 from: 
 https://www.cdc.gov/hpv/hcp/schedulesrecommendations.html?CDC_AA_refVal









Centers for Disease Control and Prevention. (n.d.). HPV Vaccine information for 
 clinicians. Retrieved from: https://www.cdc.gov/hpv/hcp/need-to-know.pdf 
Erves, J., Mayo-Gamble, T., Hull, P., Duke, L., & Miller, S. (2017). Adolescent 
 participation in HPV vaccine clinical trials: Are parents willing? Journal of 
 Community Health, 42(5), 894–901. 
 https://doiorg.library.pittstate.edu/10.1007/s10900-017-0331-x 
Ezeanolue, E., Harriman, K., Hunter, P., Kroger, A., & Pellegrini, C. (2017). 
 General best practice guidelines for immunizations. Best Practices 
 Guidance of the Advisory Committee of Immunization Practices (ACIP).  
 Retrieved from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-
 recs/index.html 
Forshaw, J., Gerver, S. M., Gill, M., Cooper, E., Manikam, L., & Ward, H. (2017). The 
 global  effect of maternal education on complete childhood vaccination: a 
 systematic review and meta-analysis. BMC Infectious Diseases, 171-16. 
 doi:10.1186/s12879-017-2890-y 
Franco, M., Mazzucca, S., Padek, M., & Brownson, R. C. (2019). Going beyond the 
 individual: how state-level characteristics relate to HPV vaccine rates in the 
 United States. BMC Public Health, 19(1), N.PAG. https://doi-
 org.library.pittstate.edu/10.1186/s12889-019-6566-y 
Gillespie, K. (2018). Adolescent vaccination coverage in Kansas, an analysis of BRFSS 









Healthy People 2020. (2014). HPV vaccine, adolescents, 2008-2012. Retrieved from: 
 https://www.healthypeople.gov/2020/topics-objectives/national-snapshot/hpv-
 vaccine-adolescents-2008%E2%80%932012 
Kasymova, S. Harrison, S. E., & Pascal, C. (2019) Knowledge and awareness of human 
 papillomavirus among college students in South Carolina. Infectious Diseases: 
 Research & Treatment, 12, N.PAG. 
 https://doiorg.library.pittstate.edu/10.1177..1178633718825077 
Kornides, M. L., Calo, W. A., Heisler-MacKinnon, J. A., & Gilkey, M. B. (2018). U.S. 
 Primary care clinics’ experiences during introduction of the 9-Valent HPV 
 vaccine. Journal of Community Health, 43(2), 291–296. https://doi-
 org.library.pittstate.edu/10.1007/s10900-017-0420-x 
Lai, D., Bodson, J., Davis, F., Lee, D., Tavake-Pasi, F., Napia, E., & Kepka, D. (2017). 
 Diverse families’ experiences with HPV vaccine information sources: A 
 community-based participatory approach. Journal of Community Health, 42(2), 
 400–412. https://doi-org.library.pittstate.edu/10.1007/s10900-016-0269-4 
Lexico. (2019). Vaccination. Retrieved from: 
 https://www.lexico.com/en/definition/vaccination 
MacArthur, K. R. (2017). Beyond health beliefs: The role of trust in the HPV vaccine 
 decision-making process among American college students. Health Sociology 










McLedo, Saul. (2019). What’s the difference between qualitative and quantitative 
 research? Retrieved from: https://www.simplypsychology.org/qualitative-
 quantitative.html 
National Cancer Institute. (n.d.). NCI dictionary of cancer terms. Retrieved from: 
 https://www.cancer.gov/publications/dictionaries/cancer-terms/def/human-
 papillomavirus 
Ogunbajo, A., Hansen, C. E., North, A. L., Okoloko, E., & Niccolai, L. M. (2016). “I 
 think they’re all basically the same”: Parents’ perceptions of human papilloma 
 virus (HPV) vaccine compared with other adolescent vaccines. Child: Care, 
 Health & Development, 42(4), 582–587. https://doi-
 org.library.pittstate.edu/10.1111/cch.12331 
Roncancio, A., Ward, K., Carmack, C., Muñoz, B., Cano, M., & Cribbs, F. (2017). Using 
 social marketing theory as a framework for understanding and increasing HPV 
 vaccine series  completion among hispanic adolescents: A qualitative study. 
 Journal of Community Health, 42(1), 169–178. https://doi-
 org.library.pittstate.edu/10.1007/s10900-016-0244-0 
Rosen, B. L., DiClemente, R., Shepard, A. L., Wilson, K. L., & Fehr, S. K. (2017). 
 Factors associated with school nurses’ HPV vaccine attitudes for school-aged 
 youth. Psychology, Health & Medicine, 22(5), 535–545. https://doi-
 org.library.pittstate.edu/10.1080/13548506.2016.1173710 
Satterwhite, C.L., Torrone, E., Meites, E., Dunne, E.F., Mahjan, R., Ocfemia, M.C., &
 Weinstock, H. (2013). Sexually transmitted infections among US women and 









Steinau, M., Unger, E.R., Hernandez, B.Y., Goodman, M.T., Copeland, G., Hopenhayn, 
 C., Cozen, W., Saber, M.S., Huang, Y., Peters, E.S., Lynch, C.F., Wilkinson, E. 
 J., Rajeevan, M.S., Lyu, C. & Saraiya, M. (2013). Human papillomavirus 
 prevalence in invasive anal cancers in the United States before vaccine 
 introduction. Journal of Lower Genital Tract Disease, 17, 397-403.  
University of Twente. (2017). Health belief model. Retrieved from: 
 https://www.utwente.nl/en/bms/communication-theories/sorted-
 bycluster/Health%20  Communication /Health_Belief_Model/  
Ventola, C. L. (2016). Immunization in the United States: Recommendations, barriers, 
 and measures to improve compliance: Part 1: Childhood vaccinations. Pharmacy 
 and Therapeutics, 41(7), 426–436. 
Wilson, A. R., Hashibe, M., Bodson, J., Gren, L. H., Taylor, B. A., Greenwood, J., &
 Kepka, D. (2016). Factors related to HPV vaccine uptake and 3-dose completion 
 among women in a low vaccination region of the USA: an observational study. 
 BMC Women’s Health, 16, 1–9. https://doi-
 org.library.pittstate.edu/10.1186/s12905-016-0323-5 

















































Appendix A:  
Pretest –  
 
First initial of mother’s first name: 
First initial of mother’s maiden name: 
First initial of your middle name (If none, use X):  
First initial of place of birth: 
 
 





Ever heard of HPV? 
Yes 
No/Do not know 
Ever heard of the HPV vaccine? 
Yes 
No/Do not know 
Has a healthcare provider recommended the HPV vaccine to you? 
Yes  
No/Do not know 
Have you received at least once dose of the HPV vaccine? 
Yes 
No/Do not know 
 
Human Papillomavirus Knowledge Questionnaire (HPV-KQ) 
 
For each statement, please circle “True” (T), “False” (F), or “I don’t know” (DK).  
If you do not know, please do not guess, please circle “DK.” 
    
        True       False       I don’t 
know 
1. HPV is a sexually transmitted infection. T F DK 
2. There is a cure for HPV.  T F DK 
3. Having one type of HPV means that you cannot acquire new 
types.  
T F  
DK 
4. There is a screening that is commonly used to test males for 
HPV.  










5. An abnormal Pap smear may indicate that a woman has HPV.   T  F  
DK 
6. Most genital HPV infections do not clear up on their own. T F DK 
7. A person usually has symptoms when infected with HPV.  T F DK 
8. HPV is not a very common virus.  T F DK 
9. HPV infection can cause genital warts.  T F DK 
10. HPV infection can cause genital herpes.  T F DK 
11. Certain types of HPV can lead to cervical cancer in women.  T F DK 
12. HPV can lay dormant in the body for years without 
symptoms. 
T F DK 
13. A person’s chances of getting HPV increase with the number 
of sexual partners they have.  
T F DK 
14. Most people with HPV have visible signs or symptoms of the 
infection.  
T F DK 
15. Genital warts can cause cervical cancer.  
 
T F DK 
16. Condoms are not effective in preventing HPV.  T F DK 
17. HPV can cause penile cancer.  T F DK 
18. Nearly all sexually active men and women will contract HPV 
at some point.  


















Appendix B:  
Posttest–  
 
First initial of mother’s first name: 
First initial of mother’s maiden name: 
First initial of your middle name (If none, use X):  
First initial of place of birth: 
 
If you have not received one does of the HPV vaccine, do you intend to after the 
education? 
I have already received at least one dose  
Yes 
No/Do not know 
 
Human Papillomavirus Knowledge Questionnaire (HPV-KQ) 
For each statement, please circle “True” (T), “False” (F), or “I don’t know” (DK).  
If you do not know, please do not guess, please circle “DK.” 
    
         True       False     I don’t 
know 
1. HPV is a sexually transmitted infection. T F DK 
2. There is a cure for HPV.  T F DK 
3. Having one type of HPV means that you cannot acquire new 
types.  
T F  DK 
4. There is a screening that is commonly used to test males for 
HPV.  
 T  F  DK 
5. An abnormal Pap smear may indicate that a woman has HPV.   T  F  DK 
6. Most genital HPV infections do not clear up on their own.  T  F  DK 
7. A person usually has symptoms when infected with HPV.    T   F   DK 
8. HPV is not a very common virus.    T    F    DK 
9. HPV infection can cause genital warts.    T    F    DK 
10. HPV infection can cause genital herpes.    T    F    DK 









12. HPV can lay dormant in the body for years without symptoms.    T    F    DK 
13. A person’s chances of getting HPV increase with the number 
of sexual partners they have.  
T F DK 
14. Most people with HPV have visible signs or symptoms of the 
infection.  
T F DK 
15. Genital warts can cause cervical cancer.  
 
T F DK 
16. Condoms are not effective in preventing HPV.  T F DK 
17. HPV can cause penile cancer.  T F DK 
18. Nearly all sexually active men and women will contract HPV 
at some point.  































































INCREASING KNOW LEDGE ABOUT 
HPV AND THE HPV VACCINE AMONGST 
COLLEGE STUDENTS
Morgan Baxter, BSN, RN
BSN to DNP 
Pittsburg State University
W HAT IS HPV?
• Virus that infects epithelial tissues of males and females. 
• Can cause warts and several different cancers. 
• Can be asymptomatic.
• 80 million people have HPV in the United States. 
• Every year 14 million contract the virus 











W HAT IS THE 
HPV VACCINE?
• Three different vaccines to date. 
• Current vaccine is the Gardasil 9, approved in 
2014 and only one used today
• Protects against HPV types 6, 11, 16, 18, 31, 
33, 45, 52, and 58. 
• Recommended for people between the ages 
of 9 to 26. 
• 2 or 3 doses of vaccine to be fully protected 
depending on age of initial vaccination
• Healthy People 2020 goal is 80% HPV 
vaccination
HPV KNOW LEDGE
• Is HPV a sexually transmitted infection?
• Is there a cure for HPV?
• If you have one type of HPV can you acquire a different type?
• Can males be screened for HPV?
• Can an abnormal pap smear indicate a woman has HPV?
• Do most HPV infections clear up on their own?
• Does a person have symptoms when infected with HPV?
• Is HPV a common virus?












• Can HPV cause genital herpes?
• Can certain types of HPV lead to cervical cancer in women?
• Can HPV lay dormant in the body for years without symptoms?
• Does the chances of contracting HPV increase with the number of sexual 
partners they have?
• Do most people have visible signs or symptoms of the infection?
• Can genital warts cause cervical cancer?
• Can condoms prevent HPV?
• Can HPV cause penile cancer?
• Is it true nearly all sexually active men and women will contract HPV at 
some point?
SUMMARY
• HPV IS PREVENTABLE
• Vaccine available, most 
insurances covered. 
